Insider Selling: United Therapeutics (NASDAQ:UTHR) Director Sells 4,910 Shares of Stock

United Therapeutics Corporation (NASDAQ:UTHR) Director Ray Kurzweil sold 4,910 shares of the firm’s stock in a transaction dated Wednesday, March 4th. The stock was sold at an average price of $489.02, for a total transaction of $2,401,088.20. Following the transaction, the director directly owned 12,670 shares in the company, valued at approximately $6,195,883.40. This represents a 27.93% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website.

United Therapeutics Trading Down 1.1%

NASDAQ UTHR traded down $5.15 during trading on Thursday, reaching $485.06. The company’s stock had a trading volume of 420,755 shares, compared to its average volume of 381,036. The firm has a 50 day moving average price of $483.67 and a 200 day moving average price of $450.90. United Therapeutics Corporation has a 12 month low of $266.98 and a 12 month high of $537.19. The firm has a market capitalization of $21.26 billion, a price-to-earnings ratio of 17.39, a price-to-earnings-growth ratio of 1.79 and a beta of 0.84.

United Therapeutics (NASDAQ:UTHR) last released its quarterly earnings results on Wednesday, February 25th. The biotechnology company reported $7.70 earnings per share for the quarter, beating analysts’ consensus estimates of $6.78 by $0.92. The company had revenue of $790.20 million during the quarter, compared to the consensus estimate of $814.80 million. United Therapeutics had a net margin of 41.94% and a return on equity of 19.30%. The firm’s quarterly revenue was up 7.4% on a year-over-year basis. During the same period in the previous year, the business earned $6.19 earnings per share. On average, equities analysts forecast that United Therapeutics Corporation will post 24.48 EPS for the current fiscal year.

Hedge Funds Weigh In On United Therapeutics

A number of institutional investors have recently added to or reduced their stakes in the stock. Torren Management LLC acquired a new stake in United Therapeutics in the fourth quarter valued at approximately $26,000. Activest Wealth Management lifted its stake in shares of United Therapeutics by 1,400.0% in the 4th quarter. Activest Wealth Management now owns 60 shares of the biotechnology company’s stock valued at $29,000 after acquiring an additional 56 shares during the last quarter. Entrust Financial LLC bought a new position in shares of United Therapeutics in the 4th quarter valued at $31,000. Wilmington Savings Fund Society FSB boosted its holdings in shares of United Therapeutics by 125.6% during the 3rd quarter. Wilmington Savings Fund Society FSB now owns 88 shares of the biotechnology company’s stock valued at $37,000 after acquiring an additional 49 shares in the last quarter. Finally, Harbor Capital Advisors Inc. bought a new stake in United Therapeutics during the 4th quarter worth $48,000. 94.08% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of research analysts recently commented on the company. HC Wainwright raised their price target on United Therapeutics from $525.00 to $600.00 and gave the stock a “buy” rating in a research report on Thursday, February 26th. Wells Fargo & Company raised their target price on shares of United Therapeutics from $423.00 to $466.00 and gave the company an “equal weight” rating in a report on Thursday, February 26th. Oppenheimer upped their price target on shares of United Therapeutics from $575.00 to $600.00 and gave the stock an “outperform” rating in a report on Thursday, February 26th. Bank of America reissued a “neutral” rating on shares of United Therapeutics in a research note on Wednesday, February 25th. Finally, Royal Bank Of Canada upped their target price on United Therapeutics from $587.00 to $643.00 and gave the stock an “outperform” rating in a research note on Thursday, February 26th. Nine investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. According to MarketBeat.com, United Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $539.00.

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.